Back to Journals » OncoTargets and Therapy » Volume 5

Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer

Authors Fuloria J

Received 3 March 2012

Accepted for publication 20 April 2012

Published 17 August 2012 Volume 2012:5 Pages 133—142

DOI https://doi.org/10.2147/OTT.S31412

Review by Single anonymous peer review

Peer reviewer comments 3

Download Article [PDF] 

Jyotsna Fuloria

Ochsner Medical Center, New Orleans, LA, USA

Abstract: The biological agents approved for the treatment of patients with metastatic colorectal cancer – bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor A, along with cetuximab and panitumumab, two monoclonal antibodies that target the epidermal growth factor receptor – are associated with a number of adverse events that range in severity from relatively mild to potentially life threatening. Hypertension, thromboembolic events, proteinuria, bleeding, and gastrointestinal perforation have all been associated with bevacizumab, while dermatologic toxicities are common with cetuximab and panitumumab. Hypersensitivity reactions and hypomagnesemia are also a concern with cetuximab and panitumumab. The frequency of these adverse events in randomized clinical trials is reviewed, and recommendations for managing these events in patients undergoing treatment for metastatic colorectal cancer are provided.

Keywords: adverse events, antiangiogenic agents, bevacizumab, cetuximab, metastatic colorectal cancer, panitumumab

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]